Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2016 - 2018)

Vanda Pharmaceuticals' Accumulated Expenses history spans 9 years, with the latest figure at $3.4 million for Q1 2018.

  • For Q1 2018, Accumulated Expenses rose 10.69% year-over-year to $3.4 million; the TTM value through Mar 2018 reached $3.4 million, up 10.69%, while the annual FY2017 figure was $4.4 million, 2.4% up from the prior year.
  • Accumulated Expenses for Q1 2018 was $3.4 million at Vanda Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $43.6 million in Q2 2015 and bottomed at $388000.0 in Q4 2014.
  • The 5-year median for Accumulated Expenses is $4.6 million (2017), against an average of $9.8 million.
  • The largest annual shift saw Accumulated Expenses soared 3876.25% in 2015 before it tumbled 86.2% in 2016.
  • A 5-year view of Accumulated Expenses shows it stood at $388000.0 in 2014, then surged by 1273.2% to $5.3 million in 2015, then decreased by 19.46% to $4.3 million in 2016, then increased by 2.4% to $4.4 million in 2017, then decreased by 21.55% to $3.4 million in 2018.
  • Per Business Quant, the three most recent readings for VNDA's Accumulated Expenses are $3.4 million (Q1 2018), $4.4 million (Q4 2017), and $4.8 million (Q3 2017).